(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/208391 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/4375* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/IB2022/052952

(22) International Filing Date:
30 March 2022 (30.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/168,456 31 March 2021 (31.03.2021) US
63/309,346 11 February 2022 (11.02.2022) US

(71) Applicant: **PFIZER INC,** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **ALLEN, Shelley**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **BLAKE, James Francis**; 2435 Mallard Circle, Longmont, Colorado 80504 (US). **BLANCHE, Sydney Taylor**; of c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **BOYS, Mark Laurence**; 529 Goranson Ct., Lyons, Colorado 80540 (US). **CLARK, Wesley Dewitt**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **COWDREY, Connor James**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **DAHLKE, Joshua Ryan**; 2519 Danbury Dr., Longmont, Colorado 80503 (US). **DOERNER BARBOUR, Patrick Michael**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **KELLUM, Alex Andrew**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **KNAPP, Ellen Margaret**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **MORENO, David Austin**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **O'LEARY, Jacob Matthew**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **REN, Li**; 1016 Monroe Way, Superior, Colorado 80027 (US). **WITKOS, Faith**

(54) Title: 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS



(I)



FIG. 3

(57) Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4- dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.

[Continued on next page]

WO 2022/208391 A1

Elizabeth; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US).

(74) **Agent: ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route 206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New Jersey 07977 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*